Loading stock data…
FTRE
$16.88+0.31 (+1.87%)
After Hours$16.85-0.03 (-0.18%)· Last close Jun 9
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fortrea Holdings Inc. in the Healthcare sector is trading at $16.88. Wall Street consensus targets $16.21 (11 analysts), implying a -4.0% move over the next 12 months. The stock is currently near its 52-week high of $18.67, remaining 38.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$16.88
Potential Downside
0%
Whystock Fair Value$16.88
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Buy
Mean target$16.21-4.0%
Range$9.50 – $20.00
Fundamentals
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as cl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-84.98%
Volume
Today's trading volume
865,995
Recent News
3 Overrated Stocks We Approach with Caution
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
Spotting Winners: Fortrea (NASDAQ:FTRE) And Drug Development Inputs & Services Stocks In Q1
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Fortrea (NASDAQ:FTRE) and its peers.
Fortrea’s Q1 Earnings Call: Our Top 5 Analyst Questions
Fortrea’s first quarter results were well received by investors, as the company exceeded Wall Street expectations on both revenue and non-GAAP earnings. Management attributed this performance to improved commercial execution in its core clinical research services, especially a rebound in biotech client activity and a higher book-to-bill ratio for the third straight quarter. CEO Anshul Thakral emphasized the impact of deliberate efforts to diversify the customer base, with notable wins among earl
Does Fortrea (FTRE) Shrinking Losses With Flat Sales Clarify Its Path to Sustainable Profitability?
Fortrea Holdings Inc. has reported past first-quarter 2026 results, with sales of US$636.5 million versus US$651.3 million a year earlier and a net loss of US$23.6 million, while also reiterating full-year 2026 revenue guidance of US$2.55 billion to US$2.65 billion. Although revenue edged lower year on year, the sharp reduction in quarterly net loss and reaffirmed revenue outlook directly addresses earlier concerns about Fortrea’s recent performance consistency. With Fortrea’s net loss...
Is Now An Opportune Moment To Examine Fortrea Holdings Inc. (NASDAQ:FTRE)?
Fortrea Holdings Inc. ( NASDAQ:FTRE ), is not the largest company out there, but it led the NASDAQGS gainers with a...